EGIS-7625
EGIS-7625 is a selective and competitive 5-HT2B receptor antagonist. It is experimentally proven to be directly associated with smooth stomach muscle construction of white rats in vivo, and variably effective in provoking a similar response in in vitro human stomach cells. In high blood concentrations, it causes mild constriction of rabbit pulmonary arteries.[1]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H22N4O2 |
| Molar mass | 326.400 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, et al. (2003). "Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist". Cardiovascular Drugs and Therapy. 17 (5–6): 427–34. doi:10.1023/B:CARD.0000015857.96371.43. PMID 15107597. S2CID 11532969.
| Simple piperazines (no additional rings) | |
|---|---|
| Phenylpiperazines |
|
| Benzylpiperazines | |
| Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
| Pyrimidinylpiperazines | |
| Pyridinylpiperazines | |
| Benzo(iso)thiazolylpiperazines | |
| Tricyclics (piperazine attached via side chain) |
|
| Others/Uncategorized | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.